Skip to content
Disclosery

Fairmount Funds Management LLC

Follow

13F filer, CIK 1802528, WEST CONSHOHOCKEN, PA

Fairmount Funds Management LLC reported $1,512,967,797 across 12 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 97.65% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-096405

Period
2026-06-30
Reported value
$1.51B
Holdings
12
Top 10 weight
97.65%
New
1
Sold out
1

Part of the filer group Fairmount Funds Management LLC

  • Fairmount Healthcare Fund II L.P.
  • Harwin Peter Evan
  • Kiselak Tomas
How groups are built

Stakes and trades reported after 2026-06-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SYRE SPYRE THERAPEUTICS INC: 13D/A 10,185,961 shares, 9.99% of the class, 13D/A filed 2026-10-09, 0001104659-26-115087Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VRDNadded+1,176,470$21.6M
FTHnew+722,020$18.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SYREexited-4,018,101-$203M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001104659-26-096405, largest first. % of portfolio is the value over $1,512,967,797, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,211,922 shares; 2024Q4: 3,371,922 shares; 2025Q1: 3,371,922 shares; 2025Q2: 3,371,922 shares; 2025Q3: 3,705,262 shares; 2025Q4: 3,705,262 shares; 2026Q1: 3,705,262 shares; 2026Q2: 3,705,262 shares 3,705,262$353M23.31%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,700,691 shares; 2024Q4: 2,700,691 shares; 2025Q1: 2,700,691 shares; 2025Q2: 2,707,191 shares; 2025Q3: 3,307,191 shares; 2025Q4: 2,137,191 shares; 2026Q1: 2,537,191 shares; 2026Q2: 2,537,191 shares 2,537,191$247M16.35%0Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 8,713,000 shares; 2026Q2: 8,713,000 shares 8,713,000$227M14.98%0Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,225,641 shares; 2024Q4: 6,225,641 shares; 2025Q1: 6,225,641 shares; 2025Q2: 6,225,641 shares; 2025Q3: 9,003,418 shares; 2025Q4: 9,003,418 shares; 2026Q1: 5,503,418 shares; 2026Q2: 5,503,418 shares 5,503,418$213M14.08%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,220,368 shares; 2025Q3: 3,220,368 shares; 2025Q4: 4,553,494 shares; 2026Q1: 4,553,494 shares; 2026Q2: 4,553,494 shares 4,553,494$101M6.69%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,202,798 shares; 2024Q4: 3,202,798 shares; 2025Q1: 3,202,798 shares; 2025Q2: 3,711,444 shares; 2025Q3: 3,711,444 shares; 2025Q4: 3,711,444 shares; 2026Q1: 1,855,644 shares; 2026Q2: 1,855,644 shares 1,855,644$94.2M6.22%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,445,813 shares; 2024Q4: 3,445,813 shares; 2025Q1: 3,445,813 shares; 2025Q2: 3,459,913 shares; 2025Q3: 3,459,913 shares; 2025Q4: 3,914,458 shares; 2026Q1: 3,914,458 shares; 2026Q2: 5,090,928 shares 5,090,928$93.5M6.18%+1,176,470Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,892,806 shares; 2024Q4: 1,892,806 shares; 2025Q1: 1,892,806 shares; 2025Q2: 1,892,806 shares; 2025Q3: 1,892,806 shares; 2025Q4: 2,209,025 shares; 2026Q1: 2,359,025 shares; 2026Q2: 2,359,025 shares 2,359,025$59.9M3.96%0Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,387,866 shares; 2025Q3: 1,387,866 shares; 2025Q4: 2,747,866 shares; 2026Q1: 2,747,866 shares; 2026Q2: 2,747,866 shares 2,747,866$49.5M3.27%0Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,048,647 shares; 2024Q4: 2,048,647 shares; 2025Q1: 2,048,647 shares; 2025Q2: 2,048,647 shares; 2025Q3: 2,048,647 shares; 2025Q4: 2,048,647 shares; 2026Q1: 298,647 shares; 2026Q2: 298,647 shares 298,647$39.6M2.62%0Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 722,020 shares 722,020$18.1M1.19%newTimeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 6,125,000 shares; 2025Q1: 6,125,000 shares; 2025Q2: 6,125,000 shares; 2025Q3: 6,125,000 shares; 2025Q4: 8,625,000 shares; 2026Q1: 8,625,000 shares; 2026Q2: 8,625,000 shares 8,625,000$17.5M1.16%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SYRESPYRE THERAPEUTICS INC4,018,101$203Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-096405 base2026-08-14acceptance time not in the bulk data set